Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:25:32 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ENTA - ENANTA PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ENTA - Q0.212.00·15.980.113.51+0.544.2164.02,0712,87113.22  13.62  13.2217.15  4.0916:04:16Jan 0815 min RT 2¢

Recent Trades - Last 10 of 2871
Time ETExPriceChangeVolume
16:04:16Q13.510.541
16:04:16Q13.510.541
16:04:04Q13.510.541
16:01:56Q13.510.54252
16:01:39Q13.510.54660
16:01:25Q13.510.54124
16:00:06Q13.510.5477
16:00:06Q13.510.5447
16:00:06Q13.510.5416
16:00:06Q13.510.5470

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-08 07:00U:ENTANews ReleaseEnanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
2026-01-05 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-17 16:01U:ENTANews ReleaseEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
2025-11-04 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-10-20 07:00U:ENTANews ReleaseEnanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek(TM) 2025
2025-10-07 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek(TM) 2025
2025-10-02 16:01U:ENTANews ReleaseEnanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2025-09-30 21:00U:ENTANews ReleaseEnanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2025-09-30 16:11U:ENTANews ReleaseEnanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
2025-09-29 06:30U:ENTANews ReleaseEnanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
2025-09-26 16:01U:ENTANews ReleaseEnanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
2025-09-03 06:00U:ENTANews ReleaseEnanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
2025-08-21 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Participate in September Investor Conferences
2025-08-20 07:00U:ENTANews ReleaseEnanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
2025-08-11 16:02U:ENTANews ReleaseEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
2025-08-05 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
2025-07-15 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series
2025-06-11 12:34U:ENTANews ReleaseEnanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET(TM) (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
2025-05-27 07:00U:ENTANews ReleaseEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2025-05-22 07:00U:ENTANews ReleaseEnanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting